362 related articles for article (PubMed ID: 25641089)
1. Natalizumab analogon therapy is effective in a B cell-dependent multiple sclerosis model.
Häusler D; Nessler S; Kruse N; Brück W; Metz I
Neuropathol Appl Neurobiol; 2015 Oct; 41(6):814-31. PubMed ID: 25641089
[TBL] [Abstract][Full Text] [Related]
2. Epithelial V-like antigen mediates efficacy of anti-alpha₄ integrin treatment in a mouse model of multiple sclerosis.
Wright E; Rahgozar K; Hallworth N; Lanker S; Carrithers MD
PLoS One; 2013; 8(8):e70954. PubMed ID: 23951051
[TBL] [Abstract][Full Text] [Related]
3. [Natalizumab: an antibody targeting α4-integrin].
Nakahara J
Brain Nerve; 2014 Oct; 66(10):1149-58. PubMed ID: 25296869
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
Engelhardt B; Kappos L
Neurodegener Dis; 2008; 5(1):16-22. PubMed ID: 18075270
[TBL] [Abstract][Full Text] [Related]
5. A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients.
Cassotta A; Mikol V; Bertrand T; Pouzieux S; Le Parc J; Ferrari P; Dumas J; Auer M; Deisenhammer F; Gastaldi M; Franciotta D; Silacci-Fregni C; Fernandez Rodriguez B; Giacchetto-Sasselli I; Foglierini M; Jarrossay D; Geiger R; Sallusto F; Lanzavecchia A; Piccoli L
Nat Med; 2019 Sep; 25(9):1402-1407. PubMed ID: 31501610
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients.
Selter RC; Biberacher V; Grummel V; Buck D; Eienbröker C; Oertel WH; Berthele A; Tackenberg B; Hemmer B
Mult Scler; 2013 Oct; 19(11):1454-61. PubMed ID: 23439578
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
Rudick RA; Sandrock A
Expert Rev Neurother; 2004 Jul; 4(4):571-80. PubMed ID: 15853576
[TBL] [Abstract][Full Text] [Related]
8. Immunological markers of optimal response to natalizumab in multiple sclerosis.
Villar LM; García-Sánchez MI; Costa-Frossard L; Espiño M; Roldán E; Páramo D; Lucas M; Izquierdo G; Álvarez-Cermeño JC
Arch Neurol; 2012 Feb; 69(2):191-7. PubMed ID: 22332187
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab therapy for highly active pediatric multiple sclerosis.
Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
[TBL] [Abstract][Full Text] [Related]
10. Effects of natalizumab treatment on Foxp3+ T regulatory cells.
Stenner MP; Waschbisch A; Buck D; Doerck S; Einsele H; Toyka KV; Wiendl H
PLoS One; 2008 Oct; 3(10):e3319. PubMed ID: 18836525
[TBL] [Abstract][Full Text] [Related]
11. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.
Rice GP; Hartung HP; Calabresi PA
Neurology; 2005 Apr; 64(8):1336-42. PubMed ID: 15851719
[TBL] [Abstract][Full Text] [Related]
12. Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis.
Coisne C; Mao W; Engelhardt B
J Immunol; 2009 May; 182(10):5909-13. PubMed ID: 19414741
[TBL] [Abstract][Full Text] [Related]
13. Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.
Benkert TF; Dietz L; Hartmann EM; Leich E; Rosenwald A; Serfling E; Buttmann M; Berberich-Siebelt F
PLoS One; 2012; 7(12):e52208. PubMed ID: 23284936
[TBL] [Abstract][Full Text] [Related]
14. Immunotoxicity profile of natalizumab.
Wehner NG; Gasper C; Shopp G; Nelson J; Draper K; Parker S; Clarke J
J Immunotoxicol; 2009 Jun; 6(2):115-29. PubMed ID: 19589098
[TBL] [Abstract][Full Text] [Related]
15. Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
Davenport RJ; Munday JR
Drug Discov Today; 2007 Jul; 12(13-14):569-76. PubMed ID: 17631252
[TBL] [Abstract][Full Text] [Related]
16. Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.
Shirani A; Stüve O
J Immunol; 2017 Feb; 198(4):1381-1386. PubMed ID: 28167648
[TBL] [Abstract][Full Text] [Related]
17. The effects of natalizumab on the innate and adaptive immune system in the central nervous system.
Stüve O
J Neurol Sci; 2008 Nov; 274(1-2):39-41. PubMed ID: 18474372
[TBL] [Abstract][Full Text] [Related]
18. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.
Bonig H; Wundes A; Chang KH; Lucas S; Papayannopoulou T
Blood; 2008 Apr; 111(7):3439-41. PubMed ID: 18195093
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.
Harrer A; Tumani H; Niendorf S; Lauda F; Geis C; Weishaupt A; Kleinschnitz C; Rauer S; Kuhle J; Stangel M; Weber F; Uhr M; Linnebank M; Wildemann B; Jarius S; Guger M; Ayzenberg I; Chan A; Zettl U; Wiendl H; Pilz G; Hitzl W; Weber JR; Kraus J
Mult Scler; 2013 Aug; 19(9):1209-12. PubMed ID: 23093485
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.
Planas R; Jelčić I; Schippling S; Martin R; Sospedra M
Eur J Immunol; 2012 Mar; 42(3):790-8. PubMed ID: 22144343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
